Autoantibody profile as a novel biomarker for sepsis

Date Published April 20, 2026

Northeast Basic Sciences and Genetics
Developing an autoantibody profile to serve as a novel biomarker for sepsis detection.
This early-stage research project seeks to develop an autoantibody profile as a novel biomarker for sepsis. This project aims to identify characteristic autoantibody signatures that could signal the onset or progression of sepsis, a life-threatening inflammatory response. The core motivation of the work is clinical: earlier detection and intervention in sepsis can prevent organ failure and improve survival rates. By focusing on autoantibody profiles, the research seeks a biologically grounded diagnostic approach that may provide clinicians with a means to recognize sepsis sooner than current standard indicators allow.

The research is focused on discovery and validation of immunological signatures associated with sepsis. If successful, the development of an autoantibody profile would represent a novel diagnostic tool that complements existing clinical assessments and laboratory tests. Such a tool could help triage patients more effectively, guide early therapeutic decisions, and ultimately reduce the incidence of downstream complications such as multi-organ dysfunction. The project's emphasis on biomarker development aligns with the broader goal of translating mechanistic biological findings into actionable clinical tools.

While the work is exploratory, its potential implications are significant: sepsis remains a major cause of morbidity and mortality, and advances in early detection are a high priority for improving outcomes.
Learn more

COM Affiliation

Funding Type

Foundation/Non-profit

Update This Listing

Help us provide the most up-to-date information about this project.

Contact Us
Questions?

For questions about these research projects please email us.

Contact Us
This summary was generated by AACOM. The researchers and authors of this work were not involved in the curation of this summary.